Interleukin-13 pathway alterations impair invariant natural killer T-cell-mediated regulation of effector T cells in type 1 diabetes

Diabetes

Volumn 65, Issue 8, 2016, Pages 2356-2366

  Usero, Lorena ^a   Sánchez, Ana ^a   Pizarro, Eduarda ^b   Xufré, Cristina ^a   Martí, Mercè ^a   Jaraquemada, Dolores ^a   Roura Mir, Carme ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE MATARÓ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ARTICLE; CELL CONTACT; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETES CONTROL; DIABETIC PATIENT; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; NATURAL KILLER T CELL; PRIORITY JOURNAL; ADOLESCENT; ADULT; ANIMAL; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NONOBESE DIABETIC MOUSE; POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; CYTOKINES; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-13; MALE; MICE, INBRED NOD; MIDDLE AGED; NATURAL KILLER T-CELLS; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84980390926     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1350     Document Type: Article

References (52)

1. Gale EA. The discovery of type 1 diabetes. Diabetes 2001;50:217-226
2. In't Veld P. Insulitis in human type 1 diabetes: The quest for an elusive lesion. Islets 2011;3:131-138
3. Wenzlau JM, Hutton JC. Novel diabetes autoantibodies and prediction of type 1 diabetes. Curr Diab Rep 2013;13:608-615
4. Gomez-Tourino I, Arif S, Eichmann M, Peakman M. T cells in type 1 diabetes: instructors, regulators and effectors: a comprehensive review. J Autoimmun 2016;66:7-16
5. Lehuen A, Diana J, Zaccone P, Cooke A. Immune cell crosstalk in type 1 diabetes. Nat Rev Immunol 2010;10:501-513
6. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol 2013;13: 101-117
7. Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol 2013;171:8-19
8. Lin H, Nieda M, Hutton JF, Rozenkov V, Nicol AJ. Comparative gene expression analysis of NKT cell subpopulations. J Leukoc Biol 2006;80:164-173
9. East JE, Kennedy AJ, Webb TJ. Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells. Med Res Rev 2014;34:45-76
10. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-1056
11. Laloux V, Beaudoin L, Jeske D, Carnaud C, Lehuen A. NK T cell-induced protection against diabetes in V alpha 14-J alpha 281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J Immunol 2001;166:3749-3756
12. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002;17:725-736
13. Chen YG, Choisy-Rossi CM, Holl TM, et al. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J Immunol 2005;174:1196-1204
14. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006;177:3695-3704
15. Kis J, Engelmann P, Farkas K, et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2007;81:654-662
16. Kent SC, Chen Y, Clemmings SM, et al. Loss of IL-4 secretion from human type 1a diabetic pancreatic draining lymph node NKT cells. J Immunol 2005;175: 4458-4464
17. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890
18. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol 2010;11:197-206
19. Arora P, Baena A, Yu KOA, et al. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014;40:105-116
20. Ghazarian L, Simoni Y, Magalhaes I, Lehuen A. Invariant NKT cell development: focus on NOD mice. Curr Opin Immunol 2014;27:83-88
21. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005;23:877-900
22. Rapoport MJ, Mor A, Vardi P, et al. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998;11:635-642
23. Zaccone P, Phillips J, Conget I, et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999;48:1522-1528
24. Andrews AL, Holloway JW, Puddicombe SM, Holgate ST, Davies DE. Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem 2002;277:46073-46078
25. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012;61:1765-1773
26. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis. Nat Med 2006;12:99-106
27. Kasaian MT, Raible D, Marquette K, et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2. J Immunol 2011;187:561-569
28. Ocmant A, Michils A, Schandené L, Peignois Y, Goldman M, Stordeur P. IL-4 and IL-13 mRNA real-time PCR quantification on whole blood to assess allergic response. Cytokine 2005;31:375-381
29. White SR, Martin LD, Stern R, Laxman B, Marroquin BA. Expression of IL-4/IL-13 receptors in differentiating human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2010;299:L681-L693
30. Campbell-Harding G, Sawkins H, Bedke N, Holgate ST, Davies DE, Andrews AL. The innate antiviral response upregulates IL-13 receptor α2 in bronchial fibroblasts. J Allergy Clin Immunol 2013;131:849-855
31. Codina-Busqueta E, Scholz E, Muñoz-Torres PM, et al. TCR bias of in vivo expanded T cells in pancreatic islets and spleen at the onset in human type 1 diabetes. J Immunol 2011;186:3787-3797
32. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004;172:6519-6523
33. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009;21:1105-1111
34. Magalhaes I, Kiaf B, Lehuen A. iNKT and MAIT cell alterations in diabetes. Front Immunol 2015;6:341
35. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002;110: 793-800
36. Wilson SB, Kent SC, Patton KT, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998;391:177-181
37. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005;23:447-485
38. Novak J, Lehuen A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine 2011;53:263-270
39. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001;194:313-320
40. Lehuen A, Lantz O, Beaudoin L, et al. Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998;188:1831-1839
41. Rydén A, Faresjö M. Altered immune profile from pre-diabetes to manifestation of type 1 diabetes. Diabetes Res Clin Pract 2013;100:74-84
42. Roivainen M, Ylipaasto P, Savolainen C, Galama J, Hovi T, Otonkoski T. Functional impairment and killing of human beta cells by enteroviruses: the capacity is shared by a wide range of serotypes, but the extent is a characteristic of individual virus strains. Diabetologia 2002;45:693-702
43. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 1998;10:75-81
44. Olsson A, Johansson U, Korsgren O, Frisk G. Inflammatory gene expression in Coxsackievirus B-4-infected human islets of Langerhans. Biochem Biophys Res Commun 2005;330:571-576
45. Russell MA, Morgan NG. The impact of anti-inflammatory cytokines on the pancreatic β-cell. Islets 2014;6:e950547
46. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003;111:677-690
47. Izuhara K, Arima K. Signal transduction of IL-13 and its role in the pathogenesis of bronchial asthma. Drug News Perspect 2004;17:91-98
48. Rasche SS, Phillips M, McInerney MF, Sercarz EE, Quinn A. IL-13Rα1 expression on β-cell-specific T cells in NOD mice. Diabetes 2011;60:1716-1725
49. Newcomb DC, Zhou W, Moore ML, et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol 2009;182:5317-5321
50. Novak J, Beaudoin L, Griseri T, Lehuen A. Inhibition of T cell differentiation into effectors by NKT cells requires cell contacts. J Immunol 2005;174: 1954-1961
51. Beaudoin L, Diana J, Ghazarian L, Simoni Y, Boitard C, Lehuen A. Plasmacytoid dendritic cells license regulatory T cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes. Eur J Immunol 2014;44:1454-1466
52. Araujo LM, Lefort J, Nahori MA, et al. Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells. Eur J Immunol 2004;34: 327-335